Drug Profile
Levomilnacipran - AbbVie/Pierre Fabre
Alternative Names: Levomilnacipran ER; 1S, 2R-milnacipran; F 2695; F2695 SR; Fetzima; Levomilnacipran SRLatest Information Update: 04 Apr 2023
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Developer AbbVie; Pierre Fabre
- Class Amides; Amines; Antidepressants; Cyclopropanes; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Major depressive disorder
- Phase III Stroke
- No development reported Pain
Most Recent Events
- 22 Feb 2023 No development reported - Phase-III for Major depressive disorder (In adolescents, In children) in USA (PO)
- 03 Mar 2021 Allergan completes a phase III trial in Major depressive disorder (In children, In adolescents) in USA (PO) in February 2021 (NCT03569475)
- 16 Dec 2020 Phase III development in Major depressive disorder (In children, In adolescents) is still ongoing in USA (PO) (NCT03569475)